I'm not sure that the term "CD30 Depletion Therapy" is technically accurate. Although CD30 serves as a target for the SGEN ADCs (as well as for other firms' anti-CD30 CAR T cells), the goal is to kill the cells that carry the marker, not to deplete the CD30 itself. As to Ricardo's sanity, I have no reason to doubt it.
Throughout the trial the date of completion of final data collection for the primary outcome measure has remained 12/2017, and the date of study completion has remained 12/2019. Clinicaltrials.gov provides a complete history of all protocol changes.
The time frame for completion hasn't changed since the trial began. The increased target enrollment probably means that they are able to recruit substantially more patients than initially planned or that the rate of outcome events is less than expected, or perhaps both.